Published in J Transl Med on September 12, 2008
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | NCT01125449
Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta (2012) 1.89
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med (2009) 1.00
Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal (2013) 0.97
Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med (2013) 0.90
Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenes Res (2010) 0.88
The effects of high concentrations of vitamin C on cancer cells. Nutrients (2013) 0.85
Phyllanthus emblica L. Enhances Human Umbilical Vein Endothelial Wound Healing and Sprouting. Evid Based Complement Alternat Med (2013) 0.83
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. J Cancer Res Clin Oncol (2016) 0.77
Modulation of Cytokines in Cancer Patients by Intravenous Ascorbate Therapy. Med Sci Monit (2016) 0.77
Inhibitory effect of a mixture containing vitamin C, lysine, proline, epigallocatechin gallate, zinc and alpha-1-antitrypsin on lung carcinogenesis induced by benzo(a) pyrene in mice. J Res Med Sci (2013) 0.75
High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report. Am J Case Rep (2016) 0.75
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res (1999) 11.32
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 9.53
Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood (2000) 9.24
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest (2000) 5.88
Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med (2003) 4.02
Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med (2002) 3.81
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res (2001) 3.30
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A (2005) 3.30
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood (2004) 2.95
Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res (2004) 2.86
Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst (1998) 2.50
Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res (2003) 2.50
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell (2003) 2.16
Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol (1999) 1.60
Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood (2003) 1.49
Ascorbic acid is cytotoxic to dividing human Tenon's capsule fibroblasts. A possible contributing factor in glaucoma filtration surgery success. Arch Ophthalmol (1990) 1.44
Intravenously administered vitamin C as cancer therapy: three cases. CMAJ (2006) 1.43
Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med (2004) 1.42
Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2000) 1.41
The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid Redox Signal (2001) 1.39
Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res (2003) 1.26
Cytotoxicity of ascorbate and other reducing agents towards cultured fibroblasts as a result of hydrogen peroxide formation. J Cell Physiol (1977) 1.24
Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol (1999) 1.22
Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res (2005) 1.16
Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther (2005) 1.15
Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol (2006) 1.05
Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci (2007) 1.04
Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. World J Gastroenterol (2003) 1.02
Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer (2001) 1.02
Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. J Pharmacol Exp Ther (1996) 0.98
Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia (2007) 0.97
Ascorbic acid-independent synthesis of collagen in mice. Am J Physiol Endocrinol Metab (2005) 0.97
Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J (2004) 0.95
Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J (2008) 0.95
Inhibition of corneal angiogenesis by ascorbic acid in the rat model. Graefes Arch Clin Exp Ophthalmol (2007) 0.90
Role of hydrogen peroxide in the inhibitory effect of ascorbate on cell growth. J Nutr Sci Vitaminol (Tokyo) (1994) 0.86
Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19
Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis (2005) 1.93
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62
Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation (2009) 1.60
Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J (2011) 1.49
Polycystic ovary syndrome: focus on platelets and prothrombotic risk. South Med J (2011) 1.44
Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol (2003) 1.41
Malignant melanoma in pigmented skin: does the current interventional model fit a different clinical, histologic, and molecular entity? Dermatol Surg (2013) 1.41
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med (2008) 1.27
Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol (2010) 1.19
Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther (2005) 1.15
Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 1.11
Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med (2009) 1.10
Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report. Int Arch Med (2010) 1.09
Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med (2010) 1.09
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood (2009) 1.04
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
Tumor vaccines in 2010: need for integration. Cell Immunol (2010) 1.02
Cord blood in regenerative medicine: do we need immune suppression? J Transl Med (2007) 0.97
Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J (2003) 0.96
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic. J Transl Med (2013) 0.96
Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol (2010) 0.96
Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol (2008) 0.95
Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J (2004) 0.95
Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J (2008) 0.95
A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS One (2012) 0.94
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod Biomed Online (2008) 0.93
Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol (2003) 0.93
Comparison of endometrial regenerative cells and bone marrow stromal cells. J Transl Med (2012) 0.92
Stem cell therapy for autism. J Transl Med (2007) 0.91
LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol (2003) 0.91
Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation (2009) 0.89
Cancer is a functional repair tissue. Med Hypotheses (2005) 0.89
Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia. J Transl Med (2011) 0.88
RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther (2010) 0.88
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem (2004) 0.87
Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer (2012) 0.87
Successful penile replantation with adjuvant hyperbaric oxygen treatment. Urology (2007) 0.87
Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. Cell Immunol (2010) 0.86
The king is dead, long live the king: entering a new era of stem cell research and clinical development. J Transl Med (2011) 0.86
Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle (2009) 0.85
Combination stem cell therapy for heart failure. Int Arch Med (2010) 0.85
Small cell lung cancer with paraneoplastic lipase production. South Med J (2010) 0.85
A simple and reliable method to blood type monkeys using serum samples. Transpl Int (2009) 0.85
Th1/Th2 xenogenic antibody responses are associated with recipient dendritic cells. Microsurgery (2007) 0.84
Circulating endothelial progenitor cells: a new approach to anti-aging medicine? J Transl Med (2009) 0.84
A novel allergen-specific therapy for allergy using CD40-silenced dendritic cells. J Allergy Clin Immunol (2010) 0.84
Antigen-specific therapy of rheumatoid arthritis. Expert Opin Biol Ther (2008) 0.83
Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes? Stem Cells Int (2011) 0.83
The bio-energetic theory of carcinogenesis. Med Hypotheses (2012) 0.83
Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59. Xenotransplantation (2010) 0.82
Novel vaccination for allergy through gene silencing of CD40 using small interfering RNA. J Immunol (2008) 0.82
Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. Int Arch Med (2012) 0.82
Acute gout during treatment with paclitaxel for metastatic melanoma. Rheumatology (Oxford) (2009) 0.82
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Resistance to anti-xenogeneic response by combining alpha-Gal silencing with HO-1 upregulation. Transpl Immunol (2008) 0.80
Cotransplantation with xenogenetic neonatal porcine sertoli cells significantly prolongs islet allograft survival in nonimmunosuppressive rats. Transplantation (2009) 0.80
On the missing link between inflammation and cancer. Dermatol Online J (2011) 0.80
Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother (2007) 0.80
Induction of RNA interference in dendritic cells. Immunol Res (2004) 0.80
Exogenous endothelial cells as accelerators of hematopoietic reconstitution. J Transl Med (2012) 0.79
Chronic lymphocytic leukemia presenting with cholecystitis-like symptoms and gallbladder wall invasion. South Med J (2010) 0.79
Immune effects of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease. Cell Immunol (2008) 0.79
Mitochondria, Energy and Cancer: The Relationship with Ascorbic Acid. J Orthomol Med (2010) 0.79
A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures. J Transl Med (2006) 0.78
Inhibition of human breast carcinoma cell proliferation by ascorbate and copper. P R Health Sci J (2002) 0.78
Effects of a high molecular mass Convolvulus arvensis extract on tumor growth and angiogenesis. P R Health Sci J (2002) 0.78
Cell membrane fatty acid composition differs between normal and malignant cell lines. P R Health Sci J (2004) 0.78
Tumor growth parameters of in-vivo human breast carcinoma: a proposed mathematical model for tumor growth kinetics. P R Health Sci J (2006) 0.77
Regulation of allergy with RNA interference. Crit Rev Immunol (2009) 0.77
Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation (2003) 0.77
Anti-CD(45)RB monoclonal antibody induces immunologic toleration by suppressing dendritic cells. Transpl Immunol (2009) 0.77
Oligonucleotide based-strategies for allergy with special reference to siRNA. Expert Opin Biol Ther (2009) 0.76
Generalized cerebral atrophy seen on MRI in a naturally exposed animal model for Creutzfeldt-Jakob disease. J Transl Med (2010) 0.76
Orthomolecular oncology: a mechanistic view of intravenous ascorbate's chemotherapeutic activity. P R Health Sci J (2002) 0.76
Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy. J Transl Med (2014) 0.76
Rapidly fatal acute ATLL emerging after methotrexate therapy for disseminated psoriasis. Clin Lymphoma Myeloma Leuk (2011) 0.76
Therapeutic use of Aldara in chronic myeloid leukemia. J Transl Med (2007) 0.76
Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis. Blood Purif (2010) 0.76
Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma. Oncol Rep (2009) 0.76
Nutraceutical augmentation of circulating endothelial progenitor cells and hematopoietic stem cells in human subjects. J Transl Med (2010) 0.75